What Pfizer's Upgrade Means For Mutual Fund Investors (PFE)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Pfizer logo in blue

News

What Pfizer's Upgrade Means For Mutual Fund Investors (PFE)

Shauna O'Brien Mar 23, 2015

On Monday morning, Jefferies boosted its price target on Pfizer (PFE). Here’s what the upgrade means for mutual fund investors.

Inside the Upgrade

Jefferies analyst Jeffrey Holford has boosted its price target on Pfizer from $42 to $45. This new price target suggests a 28% upside from the stock’s current price. The firm has also added PFE to its “Franchise Picks” list.

The firm has raised its 2015 EPS estimates from $2.07 to $2.08. FY2016 EPS estimates were increased from $2.21 to $2.30.

The analyst commented: “We expect PFE shares to significantly appreciate over the next 1-2 years based on a better than expected launch of Ibrance, greater appreciation of the durable growth on offer in GEP, further accretive and potentially tax-driven M&A, and the separation of GEP by 2017 at a minimum from the rest of the business.”


Growth and Income

So far in 2015, shares of Pfizer have gained about 12%. While the company has outperformed the S&P 500, it failed to beat the pharmaceuticals industry as a whole.

The stock has grown at a steady rate over the last few years and has a dividend yield of about 3.2%. Pfizer stock is perhaps most ideal for income-focused investors that are planning on holding the stock over the long-haul.


Mutual Funds to Watch

The funds listed below may be a good option for investors seeking exposure to PFE. The three funds below currently hold the largest stakes in the company.

The Bottom Line

The funds highlighted above offer investors a stake in PFE, while remaining diversified. Investors interested in PFE may also be interested in Merck (MRK) or Johnson & Johnson (JNJ).

If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book